Having access to cutting-edge eye care technology can make a world of difference in a patient’s healthcare experience. This is particularly important for patients impacted by Dry Eye Syndrome (DES), as this condition can easily remain undetected without the proper tools. The InflammaDry diagnostic test is a great solution to ensure that the presence of DES does not go unnoticed so that patients are receiving the highest quality of care available.
Living with Dry Eyes
DES is a common inflammatory disease of the eye. Typical symptoms range from mere itching and tearing to a burning sensation, or even feeling like there is a rock in your eye. Living with dry eyes has proven to be debilitating and disheartening for many patients, as these symptoms can affect everyday life, making it difficult to perform tasks such as reading or using an electronic device.
An ongoing problem with properly diagnosing DES is that patients often experience symptoms of this disease before the eyes begin to show clinical signs. This can make it difficult for the physician to properly identify what is causing the patients’ current condition. For years, doctors have relied on different diagnostic tools to help evaluate a patient’s tear production and quality. While these tools have proven to be helpful in assessment, they do not help identify the underlying cause of dry eyes: inflammation.
Inflammation and Dry Eye Syndrome
Studies have shown that MMP-9 is an inflammatory marker that is always elevated in patients with DES. Rapid Pathogen Screening, Inc. (RPS), a company dedicated to developing modern and more efficient diagnostic tests, has invested time and resources in researching this problem. As a result, the InflammaDry diagnostic test is now available. This easy to perform, in-office test, can detect in as little as 10 minutes if a patient’s MMP-9 marker is elevated. The knowledge that inflammation is present can assist the doctor in making the correct diagnosis.
Having this information is beneficial, not only for those who are experiencing symptoms but also for patients who will undergo ocular surgery. Properly treating DES prior to surgery has shown to improve post-surgical outcome and decrease the risk of complication.
At Elmquist Eye Group, it is our goal to have the best and latest technology available to benefit our patients’ eye care experiences. With this purpose in mind, we have now incorporated the InflammaDry diagnostic test as a valuable tool to help our Dry Eye Syndrome patients.
If you would like to learn more about this tool or have concerns about your vision, Dr. E. Trevor Elmquist, Dr. Kate Wagner, Dr. Nina Burt, and Dr. Sarah Eccles-Brown of Elmquist Eye Group are available to answer your questions. With over 20 years of service to the Southwest Florida community, Elmquist Eye Group offers experienced doctors that are dedicated to patient care. Elmquist Eye Group’s Cape Coral office is located at 2336 Surfside Blvd., Suite 121, and additional offices are located in Fort Myers and at Shell Point. For more information, visit www.Elmquist.com, call 239-936-2020 or stop by an Optical Boutique location in Cape Coral or Fort Myers.